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Association of serum calcium and heart 
failure with preserved ejection fraction 
in patients with type 2 diabetes
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Abstract 
Background: Type 2 diabetes mellitus (T2DM) is a recognized trigger factor for heart failure with preserved ejection 
fraction (HFpEF). Recent studies show that higher serum calcium level is associated with greater risk of both T2DM 
and heart failure. We speculate that increased serum calcium is related to HFpEF prevalence in patients with T2DM.
Methods: In this cross-sectional echocardiographic study, 807 normocalcemia and normophosphatemia patients 
with T2DM participated, of whom 106 had HFpEF. Multinomial logistic regression was carried out to determine the 
variables associated with HFpEF. The associations between serum calcium and metabolic parameters, as well as the 
rate of HFpEF were examined using bivariate linear correlation and binary logistic regression, respectively. The predic-
tive performance of serum calcium for HFpEF was evaluated using the area under the receiver operating characteristic 
curve (AUC).
Results: Patients with HFpEF have significantly higher serum calcium than those without HFpEF. Serum calcium was 
positively associated with total cholesterol, triglycerides, low-density lipoprotein cholesterol, serum uric acid, HOMA-
IR and fasting plasma glucose. Compared with patients in the lowest serum calcium quartile, the odds ratio (OR) for 
HFpEF in patients in the highest quartile was 2.331 (95 % CI 1.088–4.994, p = 0.029). When calcium was analyzed as 
a continuous variable, per 1 mg/dL increase, the OR (95 % CI) for HFpEF was [2.712 (1.471–5.002), p = 0.001]. Serum 
calcium can predict HFpEF [AUC = 0.673, 95 % CI (0.620–0.726), p < 0.001].
Conclusions: An increase in serum calcium level is associated with an increased risk of HFpEF in patients with T2DM.
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Background
Heart failure (HF) is magnified in individuals with type 2 
diabetes mellitus (T2DM), in whom incidence rates are 
2–5 times greater than those in the general population [1, 
2]. Heart failure with preserved ejection fraction (HFpEF) 
constitutes approximately 50–55  % of the HF popula-
tion [3] and the prevalence of HFpEF is rising at a rate 
of around 1 % per year [4], so it is predicted that HFpEF 
will become the most prevalent phenotype of HF over the 
next decade [4, 5]. Despite robust evidence of prognos-
tic benefit using therapies with angiotensin-converting 
enzyme inhibitors, angiotensin-1 receptor blockers and 
β-blockers in heart failure with reduced ejection frac-
tion (HFrEF), all outcome trials in HFpEF to date have 
failed to demonstrate survival benefit [3, 6]. Since much 
less is known about the pathophysiology and treatment 
of HFpEF in contrast to HFrEF [5, 6], screening poten-
tial risk factors in the progression of HFpEF in diabetic 
patients is of particular importance.
Recent studies from clinical electrophysiology and 
preclinical experiments have demonstrated that abnor-
mal intracellular calcium homeostasis is a key deter-
minant in HFpEF [5, 7, 8]. Meanwhile, cumulative 
evidences reveal that an increase in serum calcium level 
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is independently associated with increased risk of T2DM 
[9, 10] and cardiovascular disease [11] even in normocal-
cemic populations.
Based on these findings, we speculate that an alteration 
in serum calcium is associated with HFpEF prevalence, 
and we conduct a cross-sectional study to evaluate rela-




A total of 807 subjects (463 men and 344 women) were 
included in this study. We recruited consecutive subjects 
aged 40 years or older who visited Renmin Hospital for 
education, evaluation, or treatment of T2DM from 2012 
to 2015.
To minimize the possibility that some abnormal condi-
tions may influence the results, patients with any of the 
following conditions were excluded: (1) history of left 
ventricular ejection fraction (LVEF) <50  % at any time; 
(2) isolated right heart failure due to pulmonary disease; 
(3) dyspnoea due to non-cardiac causes such as pulmo-
nary disease, anaemia, or severe obesity; (4) primary val-
vular or myocardial diseases, atrial fibrillation, coronary 
artery or cerebrovascular disease needing revascularisa-
tion within 3 months; (5) serum creatinine >130 μmol/L 
(normal range: 50–130  μmol/L) or urine albumin per 
gram urine creatinine (Alb/Cr) >300  mg/g; (6) uncon-
trolled thyroid diseases, history of parathyroid disease 
or vitamin D-related disorders; (7) medication history 
including vitamin D, bisphosphonate, estrogen replace-
ment therapy and diuretics which may influence calcium 
metabolism within the past 1 month; (8) serum calcium 
out of normal range from central laboratory of Renmin 
hospital (8.42–10.42  mg/dL, or 2.10–2.60  mmol/L); 
(9) serum phosphate out of normal range from central 
laboratory of Renmin hospital (3.00–4.50  mg/dL, or 
0.97–1.45 mmol/L).
HFpEF was diagnosed according to the European 
Society of Cardiology guideline [12]: (1) presence of 
symptoms and/or signs of HF; (2) LVEF ≥50 %; (3) NT-
proBNP >125  pg/mL. T2DM was diagnosed by the 
American Diabetes Association guideline [13]. Obe-
sity was defined as body mass index (BMI) ≥28  kg/m2 
according to Chinese standard [14]. Dyslipidemia was 
defined as HDL-C <1.04 mmol/L, LDL-C ≥4.14 mmol/L, 
or TG ≥2.26 mmol/L [15]. Smoking was defined as “ever 
smoked” as compared to “never smoked”. Hypertension 
was defined as systolic blood pressure (SBP) ≥140 mmHg 
and/or diastolic blood pressure (DBP) ≥90  mmHg, or 
current antihypertensive therapy. Micro-albuminuria was 
defined as Alb/Cr between 30 and 300 mg/g, and macro-
albuminuria was defined as Alb/Cr >300 mg/g.
This study was approved by the ethical review board of 
Renmin Hospital and complied with the Helsinki decla-
ration. Written informed consent was obtained from all 
participants.
Biochemical measurements
A 12-h overnight fasting venous blood sample was col-
lected in all subjects. A first morning urine sample was 
collected once a day for 3 consecutive days to estimate 
the Alb/Cr. The calcium, phosphate, uric acid, creatinine, 
albumin, total cholesterol (TC), triglycerides (TG), low-
density lipoprotein cholesterol (LDL-C), high-density 
lipoprotein cholesterol (HDL-C), and fasting plasma 
glucose (FPG) were measured by biochemical auto ana-
lyzer (Abbott C8000). Measurements of insulin and NT-
proBNP were performed by immunoassay technique on 
the Roche Elecsys 2010 systerm. HbA1c was measured 
by high performance liquid chromatography (HPLC; Bio-
Rad, Hercules, CA, USA). Serum calcium level was cor-
rected according to the formula: albumin-adjusted serum 
calcium concentration (mg/dL) =  measured serum cal-
cium concentration (mg/dL) +  0.8 ×  [4 −  serum albu-
min concentration (g/dL)] [10]. Insulin resistance was 
assessed by the homeostatic model: HOMA-IR  =  fast-
ing plasma glucose (mmol/L)  ×  fasting plasma insulin 
(mIU/L)/22.5 [16].
Echocardiography
According to the American Society of Echocardiogra-
phy [17], with patients in partial left lateral decubitus 
positions, echocardiographic examinations were per-
formed under two-dimensional guided M-mode with 
a Vingmed System 5 Doppler echocardiographic unit 
(GE Vingmed Ultrasound, Horten, Norway). Left ven-
tricular mass (LVM) was calculated by the Devereux 
formula [18]: LVM (g)  =  0.8{1.04 [([LVIDD (left ven-
tricular internal diameter, diastolic) + PWTD (posterior 
wall thickness, diastolic) +  IVSD (inter ventricular sep-
tum, diastolic)]3 − LVIDD3)]} + 0.6. Relative wall thick-
ness (RWT) was calculated as 2  ×  PWTD/LVIDD and 
increased RWT was defined as >0.42 [19]. LVM index 
(LVMI) was derived by correcting LVM for body sur-
face area [BSA (m2)  =  0.007184  ×  height(cm)0.725  ×  w
eight(kg)0.425] [20]. LVH was defined as follows: LVMI 
>115 g/m2 for men and LVMI >95 g/m2 for women [19]. 
LV geometry was defined as “normal” (both RWT and 
LVMI normal), “concentric remodeling” (increased RWT 
but normal LVMI), “eccentric hypertrophy” (increased 
LVMI but normal RWT), and “concentric hypertrophy” 
(both LVMI and RWT increased) [19]. Left atrial diam-
eter (LAD) and aortic root dimension (AOD) were also 
measured. LV systolic function was assessed by LVEF, 
and diastolic function was assessed by early to late mitral 
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inflow velocity ratio (E/A) as well as deceleration time 
(DT).
Data analysis
Continuous variables were presented as mean ±  stand-
ard deviation (SD), as well as frequencies and percent-
ages for categorical variables. Normal distribution was 
checked by Kolmogorov–Smirnov Test. HOMA-IR and 
Alb/Cr were logarithmically transformed to approximate 
normal distribution for analysis. Differences in normally 
distributed variables were determined by independent-
samples T test or One-way ANOVA. If data were non-
normally distributed or not met the homogeneity of 
variances, a nonparametric test was performed. Chi 
square tests were applied for categorical variables. Bivari-
ate linear correlation (Pearson correlation) analysis was 
carried out to evaluate the associations between albu-
min-adjusted serum calcium and metabolic parameters. 
Backward stepwise multinomial logistic regression analy-
sis was carried out to determine the variables associated 
with HFpEF and to estimate confounding factors possi-
bly disturbing the relationship between serum calcium 
and HFpEF. Binary logistic regression analysis was per-
formed using HFpEF as the dependent variable to ana-
lyze the association between serum calcium and HFpEF 
after adjusting for potential confounders. Odds ratios 
(OR) with 95 % confidence intervals (CI) were calculated 
for the relative risk of increased serum calcium level with 
HFpEF. The ability to predict HFpEF of albumin-adjusted 
serum calcium was evaluated using the area under the 
curve (AUC) in the receiver operating characteristic 
(ROC) curve. All statistical analysis were performed 
using Statistical Product and Service Solutions (SPSS) 




In this study, 807 patients with T2DM were included, 
42.6 % were female, with a mean age of 69.3 ± 12.1 years. 
The average duration of T2DM was 10.2  ±  8.3  years. 
HFpEF, hypertension, dyslipidemia, albuminuria, and obe-
sity were present in 106 (13.1 %), 417 (51.7 %), 434 (53.8 %), 
460 (57.0 %) and 116 (14.4 %) patients, respectively.
Significant differences in albumin-adjusted serum 
calcium (8.96 ±  0.36 vs. 9.22 ±  0.44  mg/dL, p  <  0.001) 
were observed between non-HFpEF and HFpEF group 
(Table  1). The patients with HFpEF had higher levels 
of NT-proBNP, lg HOMA-IR, serum uric acid, serum 
creatinine and lg Alb/Cr, longer duration of diabetes, 
greater percentage of female gender, micro-albuminuria 
and LVH (concentric hypertrophy, especially), as well as 
lower levels of serum albumin than those without HFpEF.
Serum calcium and metabolism‑related parameters
Bivariate linear correlation analysis showed that albu-
min-adjusted serum calcium level was significantly and 
positively correlated with metabolism-related param-
eters including FPG (r = 0.205, p < 0.001), lg HOMA-IR 
(r =  0.143, p  <  0.001), uric acid (r =  0.175, p  <  0.001), 
TG (r = 0.104, p = 0.003), TC (r = 0.125, p < 0.001) and 
LDL-C (r = 0.099, p = 0.005) (Table 2).
LV geometry
Table  3 showed echocardiographic characteristics cat-
egorized by albumin-adjusted serum calcium quartiles. 
From albumin-adjusted serum calcium quartile 1 (8.42–
8.70 mg/dL) to quartile 4 (9.23–10.42 mg/dL), there was 
a significantly overall upward tendency of LVH (from 
22.7 to 52.5 %, p < 0.001).
Compared to subjects in albumin-adjusted serum cal-
cium quartile 1, those in quartile 4 had significant lower 
percentage of normal LV geometry (31.8 vs. 53.6  %); by 
contrast, percentage of the subjects with LV eccentric 
hypertrophy and concentric hypertrophy increased sharply 
from 11.6 to 20.7 %, 11.1 to 31.8 %, respectively (Table 3).
LAD, IVSD, PWTD, RWT, and LVMI of subjects in 
quartile 4 were significantly higher than those in quar-
tile 1. As an indicator of systolic function, LVEF levels 
had no significant differences among groups categorized 
by albumin-adjusted serum calcium. E/A as well as DT, 
indicators of diastolic function, had significantly over-
all downward (1.14 ±  0.20 to 1.03 ±  0.23) and upward 
(190.39  ±  61.03 to 246.88  ±  49.98) tendencies, respec-
tively, from quartile 1 to quartile 4 (Table 3).
HFpEF
From albumin-adjusted serum calcium quartile 1 to 
quartile 4, percentage of the individuals with HFpEF 
increased sharply from 5.3 to 22.7 % (Table 3).
Besides the differences in albumin-adjusted serum 
calcium levels and clinical characteristics, echocar-
diographic parameters including LAD, LVIDD, LVIDS, 
IVSD, PWTD, RWT, LVMI, E/A and DT were also dif-
ferent between non-HFpEF and HFpEF group. In sub-
jects with HFpEF, compared with eccentric hypertrophy 
(20.8  %), concentric hypertrophy (45.3  %) was the pre-
dominant abnormality in LV geometry (Table 1).
To determine the variables associated with HFpEF, 
backward stepwise multinomial logistic regression anal-
ysis was developed to include albumin-adjusted serum 
calcium, serum phosphate, age, gender, BMI, LVMI, 
SBP, DBP, TC, TG, HDL-C, LDL-C, smoking, lg Alb/Cr, 
lg HOMA-IR, uric acid and HbA1c on first step. HFpEF 
was significantly associated with albumin-adjusted serum 
calcium, old age, female gender, LVMI, lg HOMA-IR and 
uric acid (Table 4).
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The binary logistic regression analysis (Table 5) showed 
the OR (95  % CI) for HFpEF according to changes in 
albumin-adjusted serum calcium concentration when 
calcium was a categorical variable (quartiles) or a con-
tinuous variable (per 1  mg/dL). In contrast to subjects 
in quartile 1 (8.42–8.70 mg/dL), there were significantly 
increased risk of HFpEF with subjects in quartile 4 
[(9.23–10.42  mg/dL), OR (95  % CI)  =  2.331 (1.088–
4.994), p = 0.029], after adjusted for possible confound-
ing factors including age, gender and obesity in model 1, 
further adjusted for smoking, hypertension, and dyslipi-
demia in model 2, and furthermore adjusted for LVMI, 
lg Alb/Cr, lg HOMA-IR and uric acid in model 3. When 
albumin-adjusted serum calcium level was analyzed as a 
continuous variable, the association between calcium and 
HFpEF maintained significantly in model 1, model 2 as 
well as model 3; and per 1 mg/dL increase, the OR (95 % 
CI) for HFpEF was [2.712 (1.471–5.002), p = 0.001] in the 
fully adjusted model.
To evaluate the predictive performance of albumin-
adjusted serum calcium for HFpEF, the AUC in ROC 
curve was calculated, which was 0.673 [95 % CI (0.620–
0.726), p < 0.001] (Fig. 1).
Discussion
Epidemiological studies have associated T2DM with 
HFpEF [5, 21, 22]. On the one hand, T2DM is a well-
known trigger factor for HFpEF which exerts important 
effects on ventricular relaxation/stiffness [5] and coro-
nary microvascular function [23]; on the other hand, 
diabetic cardiomyopathy is manifested by HFpEF other 
than HFrEF at an early stage [22]. Given that elevated 
serum calcium levels are associated with increased risks 
of T2DM [9, 10], an important question arises whether 
elevated serum calcium contributes to HFpEF prevalence 
in T2DM.
To the best of our knowledge, this is the first analysis of 
the relationship between changes in serum calcium levels 
and the risk of HFpEF that focused specifically on T2DM 
patients with normocalcemia and normophosphatemia. 
Our results showed a clear association between the ele-
vated albumin-adjusted serum calcium levels and the 
increased risk of HFpEF. Such an association is independ-
ent of the effects of age, gender, obesity, smoking, hyper-
tension, dyslipidemia, LVMI, HbA1c, Alb/Cr, HOMA-IR, 
and serum uric acid.
In our study, patients with HFpEF had significantly 
higher levels of albumin-adjusted serum calcium than 
those without HFpEF. On the other hand, patients in the 
highest serum calcium quartile had significantly greater 
percentage of HFpEF than those in the lowest quartile. 
Previous studies have demonstrated that higher serum cal-
cium levels are associated with greater risks of incident HF 
Table 1 Baseline characteristics of  subjects categorized 
by HFpEF
Characteristics HFpEF p value
No Yes
Age (years) 68.3 ± 12.3 75.8 ± 8.6 <0.001
Female, n (%) 287 (40.9) 57 (53.8) 0.013
Hypertension, n (%) 362 (51.6) 55 (51.9) 0.962
Smoking, n (%) 163 (23.3) 26 (24.5) 0.773
Duration of diabetes (year) 9.9 ± 8.0 12.4 ± 9.7 0.013
SBP (mmHg) 136.8 ± 19.6 138.1 ± 19.3 0.512
DBP (mmHg) 79.5 ± 11.1 77.6 ± 10.2 0.103
BMI (kg/m2) 24.3 ± 3.9 24.3 ± 3.1 0.946
Obesity, n (%) 102 (14.6) 14 (13.2) 0.713
Laboratory
 FPG (mmol/L) 7.77 ± 3.04 7.95 ± 3.80 0.589
 Lg HOMA-IR 0.56 ± 0.33 0.67 ± 0.32 0.001
 HbA1c (%) 8.16 ± 1.96 7.86 ± 1.77 0.134
 Albumin (g/L) 38.91 ± 4.98 36.88 ± 4.85 <0.001
 Uric acid (μmol/L) 331.77 ± 98.71 371.18 ± 113.06 0.001
 Creatinine (μmol/L) 80.51 ± 23.69 94.04 ± 27.40 <0.001
 lg Alb/Cr (mg/g) 1.68 ± 0.70 1.89 ± 0.67 0.004
 Micro-albuminuria, n (%) 389 (55.5) 71 (67.0) 0.026
 NT-proBNP (pg/mL) 189.86 ± 70.09 645.00 ± 264.26 <0.001
 TG (mmol/L) 1.81 ± 1.11 2.03 ± 1.66 0.184
 TC (mmol/L) 4.81 ± 1.15 4.74 ± 1.20 0.518
 HDL-C (mmol/L) 1.11 ± 0.34 1.13 ± 0.53 0.728
 LDL-C (mmol/L) 2.73 ± 0.84 2.66 ± 0.86 0.476
 Dyslipidemia, n (%) 370 (52.8) 64 (60.4) 0.144
 Albumin-adjusted calcium 
(mg/dL)
8.96 ± 0.36 9.22 ± 0.44 <0.001
 Phosphate (mg/dL) 3.55 ± 0.45 3.57 ± 0.48 0.698
 Calcium–phosphate product 
(mg2/dL2)
31.79 ± 4.44 32.44 ± 4.79 0.167
Echocardiographic characteristics
 LAD (mm) 37.65 ± 4.65 41.67 ± 5.77 <0.001
 AOD (mm) 32.49 ± 3.33 32.46 ± 3.04 0.927
 LVIDD (mm) 47.21 ± 4.23 48.10 ± 4.90 0.048
 LVIDS (mm) 29.95 ± 3.49 31.35 ± 4.04 0.001
 IVSD (mm) 10.60 ± 1.52 11.57 ± 1.90 <0.001
 PWTD (mm) 9.76 ± 1.27 10.46 ± 1.59 <0.001
 RWT 0.42 ± 0.07 0.44 ± 0.09 0.01
 LVMI (g/m2) 99.30 ± 21.10 118.35 ± 30.79 <0.001
 LVEF (%) 65.95 ± 5.35 66.86 ± 7.23 0.217
 E/A 1.10 ± 0.21 0.91 ± 0.20 <0.001
 DT (ms) 208.51 ± 54.79 265.70 ± 50.65 <0.001
LV geometry
 Normal, n (%) 309 (44.1) 22 (20.8) <0.001
 Concentric remodeling, n (%) 163 (23.3) 14 (13.2)
 Eccentric hypertrophy, n (%) 110 (15.7) 22 (20.8)
 Concentric hypertrophy, n (%) 119 (17.0) 48 (45.3)
  LVH, n (%) 229 (32.7) 70 (66.0) <0.001
Italic values represent p < 0.05
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[24], worse outcomes of HF [25], poorer clinical response 
to maximization of HF therapy [26]. However, the relation-
ship between serum calcium and HFpEF is unknown. Our 
study indicates that elevated serum calcium though in nor-
mal range is related to HFpEF prevalence in T2DM.
Elevated serum phosphate concentrations have been 
associated with cardiovascular events including heart 
failure through its interactions with parathyroid hor-
mone, vitamin D, and fibroblast growth factor 23 in some 
studies [27, 28]. In contrast, the third National Health 
and Nutrition Examination Survey showed that factors 
determining serum phosphate concentrations are largely 
unknown and previously observed associations of serum 
phosphate concentrations with cardiovascular events are 
unlikely to reflect differences in traditional cardiovascu-
lar risk factors [29]. Furthermore, serum phosphate have 
been more likey associated with HFrEF and eccentric 
hypertrophy rather than HFpEF and concentric hypertro-
phy [30, 31]. In line with these studies, our data do not 
support an association between serum phosphate and 
HFpEF.
LVH is associated with increased HF risk [22, 32]. 
Though eccentric hypertrophy can occur in HFpEF, ours 
and previous studies [3, 32] demonstrate that concen-
tric hypertrophy is the common form of left ventricular 
structural abnormality observed in these patients. Fur-
thermore, in patients with T2DM, serum calcium is asso-
ciated with an increased risk of LVH [33]. In accord with 
these, patients in our study with concentric hypertrophy 
had a higher but not significant level of serum calcium 
(9.13  ±  0.40 vs. 9.05  ±  0.42  mg/dL, p  =  0.083) and a 
greater percentage of HFpEF (28.7 vs. 16.7 %, p = 0.014) 
Table 2 Correlation coefficients between  albumin-
adjusted serum calcium and metabolic parameters




Age (year) 0.057 0.103
Duration of diabetes (year) 0.017 0.633
SBP (mmHg) 0.02 0.574
DBP (mmHg) −0.015 0.671
BMI (kg/m2) −0.004 0.899
FPG (mmol/L) 0.205 <0.001
Lg HOMA-IR 0.143 <0.001
HbA1c (%) 0.036 0.314
Uric acid (μmol/L) 0.175 <0.001
TG (mmol/L) 0.104 0.003
TC (mmol/L) 0.125 <0.001
HDL-C (mmol/L) −0.046 0.188
LDL-C (mmol/L) 0.099 0.005
Table 3 Echocardiographic characteristics of subjects categorized by albumin-adjusted serum calcium quartiles
Italic values represent p < 0.05
Echocardiographic characteristics Albumin‑adjusted calcium concentration (mg/dL) p value
8.42–8.70 8.71–8.94 8.95–9.22 9.23–10.42
n 207 231 171 198
HFpEF, n (%) 11 (5.3) 27 (11.7) 23 (13.5) 45 (22.7) <0.001
LVH, n (%) 47 (22.7) 87 (37.7) 61 (35.7) 104 (52.5) <0.001
LV geometry
 Normal, n (%) 111 (53.6) 95 (41.1) 62 (36.3) 63 (31.8) <0.001
 Concentric remodeling, n (%) 49 (23.7) 49 (21.2) 48 (28.1) 31 (15.7)
 Eccentric hypertrophy, n (%) 24 (11.6) 41 (17.7) 26 (15.2) 41 (20.7)
 Concentric hypertrophy, n (%) 23 (11.1) 46 (19.9) 35 (20.5) 63 (31.8)
LAD (mm) 37.79 ± 4.46 37.84 ± 4.89 38.18 ± 5.67 38.98 ± 4.98 0.025
AOD (mm) 32.73 ± 3.36 32.25 ± 3.41 32.39 ± 3.21 32.61 ± 3.14 0.42
LVIDD (mm) 47.45 ± 3.75 47.04 ± 4.83 46.95 ± 4.32 47.86 ± 4.27 0.177
LVIDS (mm) 29.67 ± 3.37 30.14 ± 3.64 30.13 ± 3.55 30.62 ± 3.77 0.072
IVSD (mm) 10.27 ± 1.45 10.85 ± 1.53 10.65 ± 1.60 11.13 ± 1.73 <0.001
PWTD (mm) 9.51 ± 1.25 9.92 ± 1.35 9.89 ± 1.20 10.09 ± 1.47 0.001
RWT 0.40 ± 0.06 0.43 ± 0.08 0.42 ± 0.06 0.42 ± 0.07 0.002
LVMI (g/m2) 94.11 ± 18.68 101.69 ± 21.65 101.00 ± 22.18 110.68 ± 27.90 <0.001
LVEF (%) 66.86 ± 5.33 65.73 ± 5.25 65.52 ± 5.81 66.12 ± 6.16 0.085
E/A 1.14 ± 0.20 1.10 ± 0.21 1.03 ± 0.21 1.03 ± 0.23 <0.001
DT (ms) 190.39 ± 61.03 203.78 ± 53.09 227.86 ± 47.37 246.88 ± 49.98 <0.001
Page 6 of 9Li et al. Cardiovasc Diabetol  (2016) 15:140 
than those with eccentric hypertrophy; however, after 
adjusted for LVMI (the index for LVH), serum calcium 
remained significantly associated with HFpEF (Table  5). 
Hence, the association between serum calcium and 
HFpEF in patients with T2DM can somewhat, but not 
fully, be explained by LVH.
As a key pathophysiological mechanism of T2DM, 
insulin resistance is not only accompanied with an 
increase in intracellular calcium [34, 35], but also posi-
tively correlated with serum calcium level in ours and 
other studies [33, 36, 37]. Meanwhile, there is increasing 
awareness regarding the associations of insulin resistance 
with myocardial diastolic dysfunction, cardiomyopathy 
and heart failure [21, 38, 39]. In line with these studies, 
our results showed a significant correlation between the 
elevated lg HOMA-IR value and the increased risk of 
HFpEF [OR (95 % CI) = 2.693 (1.366–5.310), p = 0.004].
In the current study, the binary logistic regression 
analysis showed a significantly association between 
albumin-adjusted serum calcium and HFpEF. Moreover, 
consistent with previous studies, our final model using 
Table 4 Final model using backward stepwise multinomial logistic regression analysis to  include albumin-adjusted 
serum calcium for HFpEF
Variables entered on first step: Albumin-adjusted serum calcium, serum phosphate, age, gender, BMI, LVMI, SBP, DBP, TC, TG, HDL-C, LDL-C, smoking, lg Alb/Cr, HbA1c, 
lg HOMA-IR, uric acid
B S.E. Wald df p value OR 95 % CI
Albumin-adjusted calcium 0.983 0.309 10.098 1 0.001 2.671 1.457–4.897
Age 0.064 0.012 27.076 1 <0.001 1.067 1.041–1.093
Gender −0.672 0.234 8.269 1 0.004 0.511 0.323–0.807
LVMI 0.023 0.005 24.111 1 <0.001 1.023 1.014–1.033
Lg HOMA-IR 0.991 0.346 8.18 1 0.004 2.693 1.366–5.310
Uric acid 0.003 0.001 6.726 1 0.009 1.003 1.001–1.005
Table 5 OR (95 % CI) of HFpEF according to albumin-adjusted serum calcium concentration
Values are OR (95 % CI) and p value
Model 1: adjusted for age, gender and obesity
Model 2: further adjusted for smoking, hypertension, and dyslipidemia
Model 3: further adjusted for LVMI, lg Alb/Cr, lg HOMA-IR, uric acid
Model Quartiles of albumin‑adjusted serum calcium (mg/dL) Continuous variable
8.42–8.70 8.71–8.94 8.95–9.22 9.23–10.42
n 207 231 171 198 807
Crude model 1.000 (reference) 2.358 (1.139–4.884), 0.021 2.769 (1.309–5.859), 0.008 5.241 (2.623–10.473), <0.001 4.945 (2.979–8.209), <0.001
Model 1 1.000 (reference) 2.349 (1.120–4.924), 0.024 2.514 (1.172–5.390), 0.018 4.824 (2.382–9.767), <0.001 5.295 (3.090–9.075), <0.001
Model 2 1.000 (reference) 2.433 (1.155–5.122), 0.019 2.520 (1.169–5.431), 0.018 4.813 (2.366–9.793), <0.001 5.021 (2.918–8.638), <0.001
Model 3 1.000 (reference) 1.722 (0.801–3.700), 0.164 1.657 (0.744–3.688), 0.216 2.331 (1.088–4.994), 0.029 2.712 (1.471–5.002), 0.001
Fig. 1 ROC curves of the ability of albumin-adjusted serum calcium 
to predict HFpEF
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backward stepwise multinomial logistic regression analy-
sis to include albumin-adjusted serum calcium for HFpEF 
showed that old age [3, 5], female gender [3, 5], uric acid 
[40], and HOMA-IR [21, 38, 39] were also related to an 
increased risk of HFpEF.
The potential mechanisms underlying association 
between serum calcium and HFpEF remains unclear; 
however, there are some possibilities. On the one hand, 
the elevation of serum calcium appears to function as a 
connecting link among various metabolic disorders. Ours 
and previous studies [33, 36, 37, 41–43] have demon-
strated that serum calcium level was positively and lin-
early associated with glucolipid metabolic parameters 
including FPG, HOMA-IR, uric acid, TG, TC and LDL-
C. Given that various metabolic abnormalities, such as 
diabetes [3, 5], obesity [3, 5], hyperuricemia [40], insulin 
resistance [21, 38, 39], and metabolic syndrome [21, 39, 
44] have been reported in association with abnormal left 
ventricular diastolic function, which is the fundamental 
physiopathologic mechanism responsible for the devel-
opment of HFpEF [45], the increased serum calcium level 
may correlate with HFpEF prevalence through metabolic 
abnormalities. On the other hand, serum calcium level 
has close relationship with some recognized pathological 
mechanisms of HFpEF [3] such as LVH [33] and vascular 
stiffness [11, 46]. Patients with HFpEF have a predomi-
nant abnormality in left ventricular distolic function [5], 
which is sensitive to disorders in calcium metabolism 
[47]. The increased diastolic tension is a result of elevated 
cytosolic diastolic calcium [8]. Abnormal calcium home-
ostasis is not only one of the mechanisms in HFpEF [8], 
but also a prominent feature in the transition from car-
diac compensatory hypertrophy to heart failure [48].
Several limitations of this study should be noted. 
First, in our study no serum parathyroid hormone, 
vitamin D and fibroblast growth factor 23 levels are 
available for most of the patients which may help to 
delineate the underlying mechanisms for the associa-
tion between serum calcium and HFpEF, so it is impos-
sible to absolutely exclude potential confounding factors 
including primary hyperparathyroidism and secondary 
hyperparathyroidism due to vitamin D deficiency and/
or renal insufficiency. To minimize these possibilities, we 
excluded individuals with serum calcium or phosphate 
levels outside the reference range. In addition, secondary 
hyperparathyroidism cannot account for the higher rate 
of HFpEF among patients with higher serum calcium in 
our study, because serum calcium levels are well-known 
lower or low-normal in individuals with secondary 
hyperparathyroidism. Second, the results are based on 
single serum calcium measurements; therefore, time 
course of changes in calcium is not available. Third, the 
majority of participants in our study were old Chinese, 
which may limit the generalizability of our results to 
other age-groups or ethnicities. Fourth, the sample size 
in this study is only moderate. Finally, the hospital-based 
cross-sectional study is vulnerable to sample selection 
bias and cannot establish a cause-effect relationship.
Conclusions
Our results support the reported correlation between 
calcium and glucolipid metabolism, and extend previ-
ous findings of the association between serum calcium 
and cardiovascular disease, especially heart failure. The 
increased albumin-adjusted serum calcium level, within 
the physiological ranges, is independently associated 
with HFpEF prevalence in patients with T2DM.
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